Therapeutic solutions for neurodegeneration


There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.

Alzprotect designs and develops innovative therapeutic solutions for these diseases.

Our objective: to slow down or stop neurodegeneration and, where possible, to restore some brain capacities

 Learn more about Alzprotect 

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.

Schematic diagram of the action of AZP2006

Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.

Learn more about
AZP2006 molecule

News

Alzprotect strengthens its Intellectual Property Portfolio for its First-in-Class Clinical Stage Drug Ezeprogind

Lille (France), November 23rd, 2020 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies. This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569).

This strengthens Alzprotect portfolio of patents covering Ezeprogind that were already granted in Europe (EP 2 938 597 - validated in 26 member states of the European Patent Convention), and in 11 other countries including Japan (JP 6384923) and China (CN 105008333).

All these patents will be in force until at least 27th December 2033, subject to patent term adjustment or extension, and similar applications are currently under examination in Canada and Brazil.

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries.

Alzprotect continues to expand the Ezeprogind intellectual property with the filing of two new European priority patent applications that will be extended to several other countries outside Europe directed to novel therapeutic uses for specific neurodegenerative diseases as well as new forms of the molecule intended for solid formulations of the drug.

Philippe Verwaerde, Chairman & Chief Executive Officer of Alzprotect, declared: “This new granted patent will reinforce our strong intellectual property portfolio which is a major asset for our company. I am also happy to extend it with two new applications in both therapeutic and formulation fields.

Cyrille Brantis, Intellectual Property Manager of Alzprotect, declared: “The grant of Ezeprogind composition of matter and therapeutic use patents in several major countries worldwide provides a significant protection of Ezeprogind’s intellectual property and is a key milestone for Alzprotect. The new patent applications are the outcome of years of high-quality research engaged by Alzprotect and highlight the company’s commitment to the development Ezeprogind.”  

Alzprotect is financed by the XERYS fund (Paris).

 

All news